Regorafenib → Alzheimers Disease

Original Indication

Multi-kinase inhibitor (e.g., cancer treatment)

Proposed New Indication

Repositionnement du Regorafenib pour la maladie d'Alzheimer, ciblant la neuroinflammation et la pathologie AD.

Proposed Mechanism

Targets: Neuroinflammation

Le Regorafenib est propose pour reguler la pathologie AD, la neuroinflammation et la spinogenese dendritique dans des modeles cellulaires et murins d'AD.

Evidence

Level: In silico (bioinformatics analysis), In vitro, In vivo (référence 32 dans PMID 36294870)

Source: Identification of Potential Repurposable Drugs in Alzheimer's Disease Exploiting a Bioinformatics Analysis." Fiscon G et al. J Pers Med. 2022. Et "Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD." Han K-M et al. Cells. 2020.

Reference: PubMed 36294870

Repurposing Score